Living Longer: Stage 4 Stomach Cancer (2nd line treatments)

IMG_20180425_163132

Upon failure of first line treatment for advanced/ stage 4 stomach cancer, patients with good performance status will benefit from second line treatments.

Which agent(s), chemotherapy/ biologic or immunotherapy offer longest median OS in this setting?

Second-line Treatments

UPDATE (1/7/2018)

Third-line Treatments

For some select few patients, if the patient performance status remains good, there are also data on third line palliative treatments.

  • Docetaxel: medial survival 5.3 months
  • Irinotecan: median OS 4 months – 6.6 months
  • ONO-4538 study (Nivolumab): median OS 5.3 months
  • Apatinib: median OS 6.5 months
  • INTEGRATE trial (Regorafenib): median OS 5.8 months

That’s it. Just the important numbers of the treatments available. Immunotherapy is coming soon and there will be a lot more updates in the coming years to come.

UPDATE (13/3/2018)

So, far, immunotherapy results haven’t been as successful as in lung cancer. 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s